References
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin. Liver Dis.9, 383–398 (2005).
- Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol.50, 402–411 (2009).
- Jacobson I, Brown R, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis patients: a randomized trial. Hepatology46, 971–981 (2007).
- Vuppalanchi R, Chalasani N. Non-alcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology49, 306–317 (2009).
- Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig. Liver Dis.41, 615–625 (2009).
- Abenavoli L, Aviello G, Capasso R et al. Milk thistle for non-alcoholic fatty liver disease treatment. Hepat. Mon.11(3), 173–177 (2011).
- El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J. Gastroenterol.14(26), 4120–4126 (2008).
- Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J. Gastroenterol.14, 6756–6765 (2006).
- Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology130, 1636–1642 (2006).
- Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann. Hepatol.9(S), 112–118 (2010).
- Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut55, 123–130 (2006).
- Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology122, 366–375 (2002).
- Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol.33, 106–115 (2000).
- Lo Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther.25(10), 1181–1191 (2007).
- Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World. J Gastroenterol.15(35), 4356–4364 (2009).
- Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int.31(S1), 23–28 (2011).
- Castera L, Hezode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis I patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut.53, 420–424 (2004).
- Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J. Gastroenterol.16(16), 1943–1952 (2010).
- Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology131, 470–477 (2006).
- Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology128, 636–641 (2005).
- del Campo JA, López RA, Romero-Gómez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. Dig. Dis.28(1), 285–293 (2010).
- Walsh MJ, Johnsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut55, 529–535 (2006).
- Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol.165, 1499–1508 (2004).
- Miyaaki H, Ichikawa T, Nakao K et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. Res.39, 850–855 (2009).
- Shimomura I, Matsuda M, Hammer RE et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell.6, 77–86 (2000).
- Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int.30, 447–454 (2010).